Exp Clin Endocrinol Diabetes 2013; 121 - P38
DOI: 10.1055/s-0033-1336677

Metabolic regulation of adrenomedullin, a novel marker of metabolic syndrome and type 2 diabetes, in subjects with different stages of glucose tolerance

N Rudovich 1, 2, A Sparwasser 3, O Pivovarova 1, 2, A Bergmann 4, MO Weickert 5, W Doehner 6, S Anker 7, AFH Pfeiffer 1, 2
  • 1German Institute of Human Nutrition Potsdam, Nuthetal, Germany, Clinical Nutrition, Nuthetal, Germany
  • 2Charité-Universitätsmedizin Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany
  • 3B.R.A.H.M.S GmbH (Part of Thermo Fisher Scientific), Biotechnology Centre Hennigsdorf, Germany
  • 4SphingoTec GmbH, Hohen Neuendorf, Germany
  • 5University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
  • 6Charite-Universitätsmedizin Berlin, Center for Stroke Research, Berlin, Germany
  • 7Charite-Universitätsmedizin Berlin, Applied Cachexia Research, Dept. of Cardiology, Germany

Aims: Adrenomeddulin, an antilypolitic and vasodilatory peptide predominantely secreted from fat tissue, has been suggested as a novel predictive marker of metabolic syndrome and type 2 diabetes (T2DM). Here we studied the metabolic regulation of circulating adrenomedullin by different physiological conditions.

Materials and methods: Circulating levels of adrenomedullin (measured as mid-regional proadrenomedullin, MR-proADM) were studied during 75 g oral glucose tolerance (NGT, n = 152; IGT+T2DM, n = 38), liquid meal challenge test (n = 45) and euglycemic-hyperinsulinemic clamp (n = 45).

Results: Circulating levels of MR-proADM were higher in subjects with T2DM compared with NGT (p < 0.01), and strongly correlated with age, creatinine, waist circumference and HDL-cholesterol. MR-proADM was down-regulated during OGTT and liquid meal test in all subjects, but only borderline regulation was observed in the euglycemic-hyperinsulinemic clamp.

Conclusion: We observed strong metabolic regulation of adrenomedullin in subjects with or without diabetes. Based on suggested predictive character of changes in adrenomedullin levels in subjects with metabolic syndrome and T2DM as well as in sepsis and cardiovascular dieseases, further investigations are needed to explain the role of adrenomedullin in the metabolic diseases.